

Ilse Dieussaert

Discloser Identifier: 1122823

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Vaccine Development Leader RSV Maternal Additional Information:		
Position Description:		
GlaxoSmithKline	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Ilse Dieussaert, Joon Hyung Kim, Sabine Luik, Claudia Seidl, Wenji Pu, Jens-Ulrich Stegmann, Geeta K Swamy, Peggy Webster, Philip R Dormitzer

Certification

I certify that the information provided in this disclosure is complete and accurate.

Philip Dormitzer

Discloser Identifier: 1123567

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Senior Vice President and Global Head of Vaccines R&D and of Infectious Disease Research Position Description: Responsible for Vaccines Research and Development and Infectious Disease Research Additional Information:		
GlaxoSmithKline	Stock Option	Self
Additional Information:		
Pfizer	Employment	Self
Title: Vice President and Chief Scientific Officer Viral and RNA Vaccines Position Description: Oversaw scientific aspects of viral and RNA vaccine Research and Development until Dec. 2, 2021. Additional Information:		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Convey

Joon Hyung Kim

Discloser Identifier: 1121848

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Clinical Project Lead Additional Information:		
Position Description: Oversea clinical project		
GlaxoSmithKline	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Sabine Luik

Discloser Identifier: 1123564

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Chief Medical Officer Additional Information: Position Description: As GSKs Chief Medical Officer I'm accountable benefit risk decision making, scientific research policies and standards and scientific communication standards, Quality in R&D as well ask risk mangement and regulatory compliance		
GlaxoSmithKline	Stock	Self
Additional Information: I have received vested and unvested GSK stock and continue to receive this as part of my longterm incentive compensation		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Wenji Pu

Discloser Identifier: 1121849

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Sr. Director, Statistics Additional Information:		
Position Description: Oversee the clinical trial design, clinical data analysis, and interpretation of the results		
GlaxoSmithKline	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1123565

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Statistics Leader Additional Information:		Position Description:

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

JENS-ULRICH STEGMANN

Discloser Identifier: 1123566

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GSK	Employment	Self
Title: Head of Clinical Safety and Pharmacovigilance Additional Information:		Position Description: Head of Safety
GSK	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 592795

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Data And Safety Monitoring	Self
Category: Data And Safety Monitoring Description: chair for independent data monitoring committee for clinical trials of RSV vaccine in pregnancy, advisory board for congenital CMV vaccine development Additional Information:		
Medscape	Other	Self
Category: Other Description: contributor to educational programs on congenital CMV, unrestricted grant funding from moderna to medscape Additional Information:		
Moderna	End Point Review Committee	Self
Category: End Point Review Committee Description: data review/event adjudication for trials involving cmv vaccines Additional Information:		
Pfizer	Data And Safety Monitoring	Self
Category: Data And Safety Monitoring Description: chair, data safety monitoring board for trials involving group b strep vaccine in pregnancy Additional Information:		
SANOFI PASTEUR INC.	Consultant	Self
Category: Consultant Description: educational program contributor on vaccines in pregnancy Additional Information:		
UpToDate	Other	Self
Category: Other Description: contributing author on listeria in pregnancy Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Peggy Webster

Discloser Identifier: 1121783

Disclosure Purpose: 23-05478

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: VP, Head of Clinical Safety and Pharmacovigilance, Vaccines Additional Information:		
Position Description: Head of Vaccine Safety		
GlaxoSmithKline	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Preterm birth signal and descriptive efficacy in maternal RSV vaccine trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.